Myfortic (Mycophenolic Acid)

Mycophenolic Acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo synthesis of guanosine nucleotides. By limiting guanosine availability, it suppresses proliferation of T‑ and B‑lymphocytes, which are critical for the immune response that can lead to graft rejection.

The dosage of Myfortic is individualized by the transplant physician based on the patient’s weight, renal function, concomitant medications, and therapeutic response. The prescriber determines the appropriate strength and dosing schedule, and adjustments are made according to clinical monitoring.

Myfortic is classified as pregnancy category D, indicating evidence of risk to the fetus, and it is generally avoided in pregnant women unless the potential benefit justifies the risk. It is also not recommended during breastfeeding because the drug can be excreted in milk and may affect the infant.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) differs from azathioprine and cyclophosphamide by specifically targeting IMPDH, resulting in more selective inhibition of lymphocyte proliferation. It generally offers a more favorable side‑effect profile, particularly regarding bone‑marrow suppression, but individual response and drug‑interaction potential must be considered.

Myfortic tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the tablets from moisture and direct sunlight to maintain stability throughout the shelf life.

Myfortic is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken at the same times each day as directed by the prescribing clinician.

The most serious adverse events include severe infections, leukopenia or neutropenia, anemia, hepatic dysfunction, and rare but potentially fatal conditions such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for blood count changes and signs of infection.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of its excipients, in pregnant women unless benefits outweigh risks, and in individuals with severe uncontrolled infections. Caution is also advised for patients with significant renal impairment.